It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock has declined 32% over the past three months.

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 8.5% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s ...

In 2021, Regeneron reported total revenue of $16.1 billion, representing an increase of 89% compared to the previous fiscal year. That's a rare performance for the biotech giant.

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter ...

Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Going by historical performance, there is a higher chance of a fall for REGN stock over the next month. A move of 16% or more in a month for REGN has occurred 176 times in the past ten years.

In 2021, Regeneron reported total revenue of $16.1 billion, representing an increase of 89% compared to the previous fiscal year. That's a rare performance for the biotech giant.

Regeneron Pharmaceuticals’ stock price increased from $376 per share at the end of 2017 to about $585 currently, a substantial increase of about 56%.